On June 29, 2026, Medicare launched the Medicare GLP-1 Bridge program, designed to provide coverage for GLP-1 medications used in obesity treatment.
This initiative targets nearly four million Medicare beneficiaries who may qualify under the established eligibility criteria.
The program represents a significant step in addressing obesity among Medicare recipients, potentially enhancing access to necessary treatments.
Updates
Update at 17:59 UTC on 2026-06-29
KFF reported Medicare has launched a temporary program covering GLP-1s for obesity for people with Medicare, known as the Medicare GLP-1 Bridge. This analysis estimates the number of Medicare Part D enrollees who could potentially qualify for the Bridge.
Sources: KFF